Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Atopic dermatitis patients achieved freedom from itch on JAK inhibitor upadacitinib

Publish date:: June 27, 2019

Key clinical point: Treatment with the Janus kinase 1 selective inhibitor upadacitinib significantly improved itch versus placebo in patients with moderate to severe atopic dermatitis

Major finding: The placebo-adjusted difference in average pruritus Numerical Rating Scale scores was highest in the 30-mg daily group, at 37.7% by week 16 (P less than .001).

Study details: A post hoc analysis of a randomized, phase 2b study including 167 patients with moderate to severe atopic dermatitis.

Disclosures: Support for the study was provided by AbbVie. Dr. Reich reported disclosures related to AbbVie, Affibody, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo Pharma, Eli Lilly, Medac Pharma, Merck, Novartis, Pfizer, Regeneron, Takeda, UCB, and XenoPort.

Citation:

REPORTING FROM WCD2019

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Dermatology

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

Study results support screening rosacea patients for cardiometabolic disease,

No lab monitoring needed in adolescents on dupilumab,